GSK plc (BCBA:GSK)

Market Cap	139.12T
Revenue (ttm)	59.26T
Net Income (ttm)	10.12T
Shares Out	n/a
EPS (ttm)	2,447.74
PE Ratio	13.75
Forward PE	n/a
Dividend	464.72 (2.57%)
Ex-Dividend Date	Nov 14, 2025

Volume	7
Average Volume	463
Open	18,210
Previous Close	17,350
Day's Range	18,100 - 18,210
52-Week Range	9,550 - 19,710
Beta	n/a
RSI	45.87
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: GSK

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP